400 µg of MBX 2109 once-weekly by subcutaneous injection
MBX-2H1004
Phase 2 small_molecule active
Quick answer
400 µg of MBX 2109 once-weekly by subcutaneous injection for Hypoparathyroidism is a Phase 2 program (small_molecule) at MBX Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MBX Biosciences
- Indication
- Hypoparathyroidism
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active